year 17, Issue 1 (January - February 2023)                   Iran J Med Microbiol 2023, 17(1): 126-127 | Back to browse issues page

XML Persian Abstract Print

Department of Biotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran ,
Abstract:   (1154 Views)

Coronavirus disease 2019 (COVID-19) is the highly viral infectious disease caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) virus (WHO, 2021). As of 5 August 2022, more than 587 million people had already been infected with around 6.4 million deaths (, 5 August). After the alpha, beta, gamma, and delta variants, the omicron (B.1.1.529) was emerged in Botswana. The original variant of omicron was named as B.1 and following the original BA.1 variant, several subvariants of Omicron have detected: BA.2, BA.3, BA.4, and BA.5 (Yao et al., 2022). Although the data related to the sub-variants before BA.5 show that the percentage of hospitalization due to Omicron has decreased compared to the previous variants (alpha, beta, gamma and delta), but the coronavirus is still considered as a serious threat to humans.

Full-Text [PDF 328 kb]   (566 Downloads) |   |   Full-Text (HTML)  (352 Views)  
Type of Study: Letter to the Editor | Subject: Medical Virology
Received: 2022/08/23 | Accepted: 2022/10/8 | ePublished: 2023/01/20

1. WHO. Coronavirus disease (COVID-19): How is it transmitted? 2021.
2. Mathieu E, Ritchie H, Rodés-Guirao LC, Cameron Appel, Joe Hasell G, Saloni BM, Diana B, et al. "Coronavirus Pandemic (COVID-19) Published online at; 2020 [Available from:
3. Yao L, Zhu KL, Jiang XL, Wang XJ, Zhan BD, Gao HX, et al. Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect Dis. 2022;22(8):1116-7. [DOI:10.1016/S1473-3099(22)00410-8] [PMID]
4. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-16. [DOI:10.1016/S0140-6736(21)02183-8] [PMID]
5. AlKaabi N, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, et al. Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial. medRxiv Infect Dis. 2022:2021.12.29.21268499. [DOI:10.1101/2021.12.29.21268499]
6. Pavot V, Berry C, Kishko M, Anosova NG, Huang D, Tibbitts T, et al. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nat Commun. 2022;13(1):1699. [DOI:10.1038/s41467-022-29219-2] [PMID] [PMCID]
7. Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, et al. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. Immunology. 2022;167(3):340-53. [DOI:10.1111/imm.13540] [PMID] [PMCID]
8. Wang J, Deng C, Liu M, Liu Y, Li L, Huang Z, et al. Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the Receptor Binding Domain. medRxiv. 2022:2022.02.19.22271215. [DOI:10.1101/2022.02.19.22271215]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.